Videos

The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.

Neurology News Network for the week ending May 25, 2019.

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.

The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.

Neurology News Network for the week ending May 18, 2019.

The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition and assessments in pediatric stroke, and how ultimately, awareness of the condition is a huge step toward achieving this goal.

The staff neurologist at Cleveland Clinic shared his insight from the study, as well as what these data can do to further inform the use of this biomarker in progressive MS trials.

How are you counseling patients and families about the risks and benefits of playing sports with repetitive head blows and the risk of CTE?

The International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.

The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.

The director of Translational Research and Epilepsy Clinical Trials at NYU Langone spoke about the nuance involved in diagnosing epilepsy and the misconceptions about how seizures present in the majority of patients.

The director of Child and Adolescent Psychiatry at Mount Sinai Health System spoke about the results of the phase 2 study of OV101 (gaboxadol), and the next steps for the phase 3 trial.

The professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.